Clinical trials: Coagulation Defect, open to volunteers
Immune Thrombocytopenia, Treatment
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy…
- Trial name
- NCT06281327
- Testing
- Avatrombopag
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Post-acute Infectious Syndrome (PAIS), Post-COVID-19 Condition (PCC or Long COVID)
Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)
Post-acute infectious syndrome (PAIS), including post-COVID-19 condition (PCC or Long COVID), can develop after an infection and may cause persistent symptoms such as fatigue, problems with memory and concentration ("brain fog")…
- Trial name
- PAISE-AriSE (NCT07714213)
- Testing
- Aripiprazole (low-dose, 1mg)
- Where
- Germany
- Volunteers
- 138 people
- Sponsor
- Christiana Franke
Hemophilia
Feasibility and Safety of Blood-Flow-Restriction Training in Patients With Hemophilia
In the course of a cross-over study design, 12 patients with hemophilic arthropathy will perform a training load on the knee extensor muscles.
- Trial name
- NCT07259356
- Testing
- Control, BFR Exercise (50% of the LOP) while Leg Press Exercise (4 Sets, All out)
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- University Hospital, Bonn
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Primary Immune Thrombocytopenia (ITP)
Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial
This prospective, multicenter, randomized study aim to evaluate the efficacy and safety of romiplostim N01 combined with glucocorticoids as the first-line treatment for newly diagnosed adult primary immune thrombocytopenia (ITP).
- Trial name
- NCT06992128
- Testing
- Romiplostim N01 combined with dexamethasone, Dexamethasone monotherapy
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Glanzmann Thrombasthenia
Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)
This study is evaluating an investigational drug, eptacog beta (EB), for the treatment and prevention of acute bleeding episodes in people with Glanzmann Thrombasthenia, a rare inherited bleeding disorder.
- Trial name
- STRENGTH (NCT07136857)
- Testing
- EPTACOG BETA
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Emory University
Hemophilia, Embolization
Embolization in Hereditary Coagulopathies
This is a longitudinal, prospective study, which will include 30 subjects with hereditary coagulopathies, with arthropathy, chronic synovitis resulting from hemarthrosis of the elbows, knees and/or ankles followed up at the…
- Conditions
- Hemophilia, Embolization, Hemarthrosis, Clotting Factor Deficiency
- Trial name
- EHCO (NCT05629130)
- Testing
- embolization with spherical microparticles embosphere
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- University of Sao Paulo General Hospital
Hemophilia a with Inhibitor
Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)
Hemophilia A is a blood coagulation disorder caused by deficient or dysfunctional clotting factor VIII (FVIII) leading to incomplete haemostasis.
- Trial name
- NCT06864975
- Testing
- Advate®
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Runhui WU
Polycythemia Vera, Essential Thrombocythemia
A Study of GLB-001 in Patients With Myeloid Malignancies
Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes
- Trial name
- NCT06378437
- Testing
- GLB-001
- Where
- 14 sites in China
- Volunteers
- 108 people
- Sponsor
- Hangzhou GluBio Pharmaceutical Co., Ltd.
Von Willebrand Diseases
A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients With VWD
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy…
- Trial name
- EMPOWER (NCT06205095)
- Testing
- Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Unity Health Toronto
Sepsis, Sepsis and Coagulopathy
Sepsis-associated Thrombocytopenia and Platelet Transfusion （STAPT）
Currently, there are no multicenter studies on platelet transfusion for SAT patients, and the benefits and risks of platelet transfusion still require further validation based on large-sample data.
- Trial name
- NCT07230067
- Testing
- SAT patients
- Where
- China
- Volunteers
- 1,500 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Immune Thrombocytopenia (ITP)
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
The Phase 1 is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RXIM002 in patients with relapsed or refractory autoimmune cytopenias.
- Trial name
- POPULUS-1 (NCT07765966)
- Testing
- RXIM002
- Volunteers
- 27 people
- Sponsor
- RiboX Therapeutics Ltd.
Women With Coagulation Disorders
Effect of Ginger on Heavy Menstrual Bleeding in Women With Coagulation Disorders
The GINGER-BLEED study is a randomized, double-blind, placebo-controlled clinical trial evaluating the effect of ginger powder on heavy menstrual bleeding in women with coagulopathies.
- Trial name
- GINGER-BLEED (NCT07595640)
- Testing
- Ginger
- Volunteers
- 74 people
- Sponsor
- University of Valladolid
Thrombotic Microangiopathies, ITP Immune-Mediated Thrombocytopenia
TGD001 Treatment in Thrombotic Microangiopathies
This is a Phase 1/2, prospective, adaptive design trial of TGD001 in participants with suspicion or clinical diagnosis of acute immune thrombotic thrombocytopenic purpura (iTTP) episodes and participants with suspicion or…
- Trial name
- NCT07459114
- Testing
- TGD001
- Volunteers
- 70 people
- Sponsor
- TargED Biopharmaceuticals B.V.
Von Willebrand Diseases, Glanzmann Thrombasthenia
Videomicroscopy for the Prediction of Bleeding in Constitutional Haemorrhagic Diseases
In Willebrand disease, there is currently no test available to identify non-invasively patients with a high risk of bleeding from angiodysplasias The study propose to use a sublingual capillary bed analysis by video-microscopy, a…
- Trial name
- VIDEO-BLEED (NCT04119908)
- Testing
- Sublingual videomicroscopy, blood sample
- Where
- France
- Volunteers
- 400 people
- Sponsor
- University Hospital, Lille
Chronic Immune Thrombocytopenia
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
The goal of the global Phase 1/2 clinical trial is to evaluate whether CID-103, a novel anti-CD38 monoclonal antibody, is safe and effective in adults with chronic immune thrombocytopenia (ITP).
- Trial name
- NCT07017725
- Testing
- CID-103
- Where
- 6 sites in China
- Volunteers
- 75 people
- Sponsor
- CASI pharmaceuticals, Inc.
Hemophilia, Rebalancing Agents
Monitoring of Anti-TFPI in Hemophilia
During the development of anti-TFPI antibodies, thrombin generation assay (TGA) was employed using both in vitro measurements (antibodies added to blood samples) and ex vivo approaches (blood samples from patients in phase II and…
- Conditions
- Hemophilia, Rebalancing Agents, Prophylaxis
- Trial name
- EUREKA (NCT07101926)
- Testing
- blood sampling
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- Hospices Civils de Lyon
Thrombocytopenia, Immune Thrombocytopenia
Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis
Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis.
- Conditions
- Thrombocytopenia, Immune Thrombocytopenia, Myelodysplasia
- Trial name
- APAT (NCT04800458)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 225 people
- Sponsor
- University Hospital, Bordeaux
Factor X Deficiency
A Database For The Collection Of Clinical, Laboratory, And Treatment Data From Patients With Factor X Deficiency To Define The Natural History Of The Disease And Improve Patient Management
Factor X deficiency is one of the most severe rare bleeding disorders and may lead to serious spontaneous hemorrhages, particularly in patients with severe congenital forms.
- Trial name
- PRO-RBDD-FX (NCT07875478)
- Where
- 2 sites in Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Fondazione Luigi Villa
Essential Thrombocythemia, Polycythemia Vera
Ruxolitinib in Thrombocythemia and Polycythemia Vera
This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- Trial name
- NCT04644211
- Testing
- Ruxolitinib
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital